After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets
This article was originally published in PharmAsia News
Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.
You may also be interested in...
MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab
GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets
MUMBAI - British drug maker GlaxoSmithKline has announced a comprehensive product licensing deal, in what it calls a "transformational agreement" with Onco Therapies - a joint venture between South Africa's largest drug firm Aspen Pharmacare and one of India's largest generic drug exporters Strides Arcolab
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.